Biotechnology company focused on developing treatments for pulmonary arterial hypertension and other chronic diseases.
United Therapeutics Corporation, based in Silver Spring, Maryland, is a leading biotechnology firm specializing in the development and commercialization of innovative therapies aimed at addressing critical medical needs for patients worldwide. The company's robust portfolio includes a range of commercial therapies designed to treat chronic and life-threatening diseases.
Among its flagship products is Remodulin, which alleviates symptoms associated with exercise for patients suffering from pulmonary arterial hypertension (PAH). Tyvaso, another key therapy, delivers an inhaled prostacyclin analogue to enhance exercise capacity in PAH patients and those with pulmonary hypertension associated with interstitial lung disease (PH-ILD). Additionally, Orenitram, available in tablet form, aims to improve exercise capability in PAH patients.
United Therapeutics is at the forefront of advancing treatments through ongoing research and development initiatives. It is actively developing Tyvaso DPI, a dry powder inhalation version of Tyvaso, and exploring Remunity Pump, a compact pump system designed for continuous subcutaneous delivery of therapeutic agents. The company's pipeline also includes promising candidates like Ralinepag and Aurora-GT, a gene therapy product targeting vascular rebuilding in the lungs.
Established in 1996, United Therapeutics maintains strategic partnerships and collaborations with industry leaders such as DEKA Research & Development Corp., MannKind Corporation, and Arena Pharmaceuticals, Inc. These alliances enable the company to leverage cutting-edge technologies and expand its therapeutic offerings, reinforcing its commitment to innovation and patient care in the biopharmaceutical sector.